Forest Announces Federal Court Upholds Lexapro(R) Patent
Posted on: Thursday, 13 July 2006, 21:00 CDT
NEW YORK, July 13 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. said today that the U.S. District Court for the District of Delaware has determined that the U.S. patent covering escitalopram, the active ingredient in Lexapro(R), is both valid, enforceable and infringed by Ivax/Teva's proposed generic product, thereby confirming Forest's and Lundbeck's patent rights for Lexapro(R), which expire in March 2012.
(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )
Judge Joseph J. Farnan ruled in Forest's and Lundbeck's favor in a lawsuit brought by Forest and its partner H. Lundbeck A/S of Denmark against the generic manufacturer Ivax/Teva.
The patent at issue in the U.S. lawsuit is Lexapro's patent (U.S. Patent No. Re 34,712), which is set to expire in March 2012 and covers substantially pure escitalopram.
About Forest Laboratories
Forest Laboratories (http://www.frx.com/) is a US-based pharmaceutical company dedicated to identifying, developing, and delivering products that make a positive difference in peoples' lives. Forest Laboratories' growing product line includes Lexapro(R) (escitalopram oxalate), an SSRI indicated for adults for the initial and maintenance treatment of major depressive disorder and for generalized anxiety disorder; Namenda(R) (memantine HCl), an N-methyl-D-aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Benicar(R)* (olmesartan medoxomil), an angiotensin receptor blocker, and Benicar* HCT(R) (olmesartan medoxomil-hydrochlorothiazide), an angiotensin receptor blocker and diuretic combination product, each indicated for the treatment of hypertension; and Campral(R)* (acamprosate calcium), indicated in combination with psychosocial support for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation.
* Benicar is a registered trademark of Sankyo Pharma, Inc., and Campral is a registered trademark of Merck Sante s.a.s., subsidiary of Merck KGaA, Darmstadt, Germany.
Except for the historical information contained herein, this release contains "forward-looking statements" within the meaning of the Private Securities Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in the Forest Laboratories' SEC reports, including the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2006.
Photo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO
Forest Laboratories, Inc.
CONTACT: Charles E. Triano of Forest Laboratories, Inc., Vice President,Investor Relations, +1-212-224-6714, charles.triano@frx.com
Web site: http://www.frx.com/
Source: PRNewswire-FirstCall
Related Articles
- Caraco Pharmaceutical Laboratories, Ltd. Closes Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
- Forest Laboratories and H. Lundbeck A/S Enter Into Settlement Agreement With Sun and Caraco Related to LEXAPRO(R) Patent Litigation
- Caraco Pharmaceutical Laboratories, Ltd. Enters Into Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
- Novexel and Forest Laboratories Announce License Agreement for NXL 104, a Novel Broad-Spectrum Beta Lactamase Inhibitor
- Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
- Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
- Forest Laboratories, Inc. And Cypress Bioscience, Inc. Announce Positive Results of Phase III Study for Milnacipran As a Treatment for Fibromyalgia Syndrome
- Forest Laboratories Announces Acquisition of Cerexa, Inc.
- Forest Laboratories, Inc. Reports Q3'06 Diluted Earnings Per Share of $0.57 Including $0.05 Per Share Licensing Payment
- Forest Laboratories Reports Earnings Per Share of $0.59 for Q2'06
 |
 |
User Comments (0)
RSS Feeds